- Poster presentation
- Open Access
Antiviral treatment in severe acute hepatitis B
BMC Infectious Diseases volume 14, Article number: P90 (2014)
We aimed to evaluate the clinical, biological and virological impact of antiviral therapy in severe acute hepatitis B. 
Materials and methods
We performed a study in the National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Bucharest, Romania, randomizing patients between two groups initially: therapy with lamivudine 100 mg/day vs. standard of care (no antiviral therapy) and subsequently between three groups: lamivudine, standard of care and entecavir 0.5 mg/day, when this new analogue became available in Romania.
HBs antigen to antibody seroconversion was recorded by 24 weeks in 10.1% of the patients in the lamivudine group (p=0.032 compared to control), 42.9% of those in the entecavir group (p=0.053 compared to control), and 22.7% in the control (standard of care) group.
If antiviral therapy is to be considered in severe acute hepatitis B, entecavir could be regarded as an option, as it might increase the chance of HBs antigen to antibody seroconversion when administered in the first 24 weeks of infection. [2, 3] However, further studies are required to ascertain this, and to eventually determine the magnitude of the effect.
Streinu-Cercel A: Hepatitis B in the spotlight. GERMS. 2011, 1 (1): 5-
De Socio GV, Sgrelli A, Tosti A, Baldelli F: Severe acute hepatitis B treated with entecavir. Mediterr J Hematol Infect Dis. 2011, 3 (1): e2011010-
Streinu-Cercel O, Streinu-Cercel A, Preotescu LL, Streinu-Cercel A: Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. GERMS. 2012, 2 (1): 18-22. 10.11599/germs.2012.1009.
About this article
Cite this article
Streinu-Cercel, A., Streinu-Cercel, O., Negut, A.C. et al. Antiviral treatment in severe acute hepatitis B. BMC Infect Dis 14 (Suppl 2), P90 (2014). https://doi.org/10.1186/1471-2334-14-S2-P90
- Public Health
- Internal Medicine
- Infectious Disease